{
  "authors": [
    {
      "author": "Marc Uemura"
    },
    {
      "author": "Faisal Fa'ak"
    },
    {
      "author": "Cara Haymaker"
    },
    {
      "author": "Natalie McQuail"
    },
    {
      "author": "Elizabeth Sirmans"
    },
    {
      "author": "Courtney W Hudgens"
    },
    {
      "author": "Lydia Barbara"
    },
    {
      "author": "Chantale Bernatchez"
    },
    {
      "author": "Jonathan L Curry"
    },
    {
      "author": "Patrick Hwu"
    },
    {
      "author": "Michael T Tetzlaff"
    },
    {
      "author": "Adi Diab"
    }
  ],
  "doi": "10.1186/s40425-016-0157-6",
  "publication_date": "2016-09-24",
  "id": "EN114454",
  "url": "https://pubmed.ncbi.nlm.nih.gov/27660709",
  "source": "Journal for immunotherapy of cancer",
  "source_url": "",
  "licence": "CC BY-NC",
  "language": "en",
  "type": "pubmed",
  "description": "",
  "text": "We report an additional case of ipilimumab-induced Grover's disease. Interestingly, this dermatologic side effect did not appear with use of anti-PD-1 therapy in our patient. Immune analysis was performed and suggests a possible role of Th2 cells in its patholgenesis."
}